Cartesian Therapeutics Stock Analysis

Cartesian Stock Analysis Notes

About 61.0% of the company outstanding shares are owned by corporate insiders. The company recorded a loss per share of 1.33. Cartesian Therapeutics had not issued any dividends in recent years. The entity had 1:30 split on the 5th of April 2024. To find out more about Cartesian Therapeutics contact Carsten Brunn at 301 348 8698 or learn more at https://www.cartesiantherapeutics.com.

Cartesian Therapeutics Investment Alerts

Cartesian Largest EPS Surprises

View All Earnings Estimates

Cartesian Therapeutics Environmental, Social, and Governance (ESG) Scores

Cartesian Stock Institutional Investors

Note, although Cartesian Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Cartesian Market Capitalization

The company currently falls under 'Small-Cap' category with a current market capitalization of 169.54 M.

Cartesian Profitablity

Management Efficiency

Cartesian Therapeutics has return on total asset (ROA) of (0.1267) % which means that it has lost $0.1267 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (70.2926) %, meaning that it created substantial loss on money invested by shareholders. Cartesian Therapeutics' management efficiency ratios could be used to measure how well Cartesian Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 10.76, whereas Return On Tangible Assets are forecasted to decline to (0.40). At present, Cartesian Therapeutics' Net Tangible Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Current Assets Total is expected to grow to about 263.7 M, whereas Non Currrent Assets Other are forecasted to decline to about 1.3 M.

Technical Drivers

As of the 17th of February 2026, Cartesian Therapeutics shows the Mean Deviation of 3.39, risk adjusted performance of (0.00005), and Standard Deviation of 4.74. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Cartesian Therapeutics, as well as the relationship between them.

Cartesian Therapeutics Price Movement Analysis

Cartesian Therapeutics Insider Trading Activities

Cartesian Therapeutics Outstanding Bonds

Cartesian Therapeutics Predictive Daily Indicators

Cartesian Therapeutics Corporate Filings

Cartesian Therapeutics Forecast Models

Cartesian Therapeutics' time-series forecasting models are one of many Cartesian Therapeutics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Cartesian Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Cartesian Therapeutics Bond Ratings

Cartesian Therapeutics financial ratings play a critical role in determining how much Cartesian Therapeutics have to pay to access credit markets, i.e., the amount of interest on their issued debt. The threshold between investment-grade and speculative-grade ratings has important market implications for Cartesian Therapeutics' borrowing costs.

Cartesian Therapeutics Debt to Cash Allocation

Cartesian Therapeutics currently holds 13.98 M in liabilities. Note, when we think about Cartesian Therapeutics' use of debt, we should always consider it together with its cash and equity.

Cartesian Therapeutics Total Assets Over Time

Cartesian Therapeutics Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Cartesian Therapeutics uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Cartesian Therapeutics Debt Ratio

3.51

It looks as if most of the Cartesian Therapeutics' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Cartesian Therapeutics' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Cartesian Therapeutics, which in turn will lower the firm's financial flexibility.

Cartesian Therapeutics Corporate Bonds Issued

Cartesian Short Long Term Debt Total

Stock analysis is the technique used by a trader or investor to examine and evaluate how Cartesian Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Cartesian shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Cartesian Therapeutics. By using and applying Cartesian Stock analysis, traders can create a robust methodology for identifying Cartesian entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Cartesian analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Cartesian analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Cartesian Therapeutics stock analysis indicators help investors evaluate how Cartesian Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Cartesian Therapeutics shares will generate the highest return on investment. By understating and applying Cartesian Therapeutics stock analysis, traders can identify Cartesian Therapeutics position entry and exit signals to maximize returns.

When running Cartesian Therapeutics' price analysis, check to measure Cartesian Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cartesian Therapeutics is operating at the current time. Most of Cartesian Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cartesian Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cartesian Therapeutics' price. Additionally, you may evaluate how the addition of Cartesian Therapeutics to your portfolios can decrease your overall portfolio volatility.